Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QuilliChew ER in 4-5 year olds with ADHD
NCT03536390Phase 4Withdrawn
- Sponsor
- Pfizer
- Start
- Sep 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of methylphenidate hydrochloride extended-release chewable tablet in attention deficit hyperactivity disorder (ADHD), sponsored by Pfizer. Planned start Sep 2018; status: withdrawn.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03536390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03536390.